keyword
MENU ▼
Read by QxMD icon Read
search

Mesothelioma

keyword
https://www.readbyqxmd.com/read/28214659/clinical-outcomes-and-prognostic-factors-of-patients-with-advanced-mesothelioma-treated-in-a-phase-i-clinical-trials-unit
#1
Dionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, Ann Petruckevitch, Awais Jalil, Marta Capelan, Vasiliki Michalarea, Joao Lima, Nikolaos Diamantis, Jaishree Bhosle, L Rhoda Molife, Udai Banerji, Johann S de Bono, Sanjay Popat, Mary E R O'Brien, Timothy A Yap
BACKGROUND: We have previously reported a prognostic score for patients in phase I trials in the Drug Development Unit, treated at the Royal Marsden Hospital (RPS). The RPS is an objective tool used in patient selection for phase I trials based on albumin, number of disease sites and LDH. Patients with mesothelioma are often selected for phase I trials as the disease remains localised for long periods of time. We have now reviewed the clinical outcomes of patients with relapsed malignant mesothelioma (MM) and propose a specific mesothelioma prognostic score (m-RPS) that can help identify patients who are most likely to benefit from early referral...
February 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28213009/immunohistochemical-detection-of-mtap-and-bap1-protein-loss-for-mesothelioma-diagnosis-comparison-with-9p21-fish-and-bap1-immunohistochemistry
#2
Tomoyuki Hida, Makoto Hamasaki, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Akinori Iwasaki, Tatsuro Okamoto, Yoshinao Oda, Hiroshi Honda, Kazuki Nabeshima
OBJECTIVES: Differentiating malignant pleural mesothelioma (MPM) from reactive mesothelial hyperplasia (RMH) is still challenging. Detection of homozygous deletion (HD) of 9p21 region including p16(INK4A) (p16) by fluorescence in situ hybridization (FISH) and immunohistochemical detection of loss of BRCA1 associated protein 1 (BAP1), are reliable markers for MPM diagnosis. However, not all laboratories are equipped to perform 9p21 FISH; immunohistochemistry (IHC) is a more common and feasible technique...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28213004/pharmacokinetic-evaluation-of-intrapleural-perfusion-with-hyperthermic-chemotherapy-using-cisplatin-in-patients-with-malignant-pleural-effusion
#3
Hirozo Sakaguchi, H Ishida, H Nitanda, N Yamazaki, K Kaneko, Kunihiko Kobayashi
OBJECTIVES: Malignant pleural effusion (MPE) has a poor prognosis. Most patients are treated with tube thoracostomy and sclerotherapy, although its success rate is around 64%. We have investigated intrapleural perfusion with hyperthermic chemotherapy (IPHC) using cisplatin in a study with a pharmacokinetic evaluation. METHODS: Patients with MPE, performance status of 0-1, possibility of good lung expansion and Cr<1.2mg/dL were treated with IPHC. The circuit was filled with 2000mL of normal saline containing cisplatin at a dose of 80mg/m(2)...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28213002/a-phase-ii-trial-of-dovitinib-in-previously-treated-advanced-pleural-mesothelioma-the-ontario-clinical-oncology-group
#4
Scott A Laurie, Desiree Hao, Natasha B Leighl, John Goffin, Abderrahim Khomani, Ashish Gupta, Christina L Addison, Anita Bane, Jean Seely, Marc L Filion, Gregory R Pond, Mark N Levine
OBJECTIVES: Following failure of a platinum-antifolate combination regimen, there is no standard therapy for advanced malignant pleural mesothelioma (MPM). The fibroblast growth factor receptor (FGFR) signaling pathways may be a relevant target in MPM. Dovitinib inhibits multiple tyrosine receptor kinases, predominantly the vascular endothelial growth factor receptors (VEGFR), but also FGFRs, and could be active in MPM. METHODS: This open-label multicentre phase II trial [NCT01769547] enrolled fit, consenting adult patients with advanced MPM who had previously received platinum-antifolate combination chemotherapy and up to one additional line of systemic therapy...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28212571/activation-of-jnk-and-ire1-is-critically-involved-in-tanshinone-i-induced-p62-dependent-autophagy-in-malignant-pleural-mesothelioma-cells-implication-of-p62-uba-domain
#5
Jihyun Lee, Eun Jung Sohn, Sangwook Yoon, Gunho Won, Chang Geun Kim, Ji Hoon Jung, Sung-Hoon Kim
The aim of present study is to elucidate autophagic mechanism of tanshinone I (Tan I) in H28 and H2452 mesothelioma cells. Herein, Tan I exerted cytotoxicity with autophagic features of autophagy protein 5 (ATG5)/ microtubule-associated protein 1A/1B-light chain 3II (LC3 II) activation, p62/sequestosome 1 (SQSTM1) accumulation and increased number of LC3II punctae, acridine orange-stained cells and autophagic vacuoles. However, 3-methyladenine (3MA) and NH4Cl increased cytotoxicity in Tan I treated H28 cells...
February 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28205427/utility-of-brca1-associated-protein-1-immunoperoxidase-stain-to-differentiate-benign-versus-malignant-mesothelial-proliferations-in-cytologic-specimens
#6
Zulfia McCroskey, Gregg Staerkel, Sinchita Roy-Chowdhuri
BACKGROUND: Loss of BAP1 has recently been described as a highly specific marker for distinguishing malignant mesotheliomas (MM) from benign mesothelial proliferations (BMP). The aim of this study was to evaluate the utility of BAP1 in cytospin and cell block (CB) preparations. METHODS: We searched the database at our institution for cases of MM (n = 21) and BMP (n = 11). A Papanicolaou stained cytospin preparation and CB section from each case were selected for BAP1 staining...
February 16, 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/28205183/large-primary-pleural-synovial-sarcoma-with-severe-dyspnea-a-case-report
#7
Minoru Yamaki, Shuji Yonehara, Toshio Noriyuki
BACKGROUND: Synovial sarcoma is a malignant neoplasm of soft tissues. It occurs mainly in the extremities and is closely related to tendons, tendon sheaths, and bursal structures. Primary synovial sarcoma of the pleura and lungs is extremely rare. CASE PRESENTATION: We present the case of a 62-year-old man with a large synovial sarcoma of the left pleura. He presented with general fatigue and severe dyspnea. Chest computed tomography (CT) revealed a 20-cm tumor in the left thoracic cavity...
December 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28199684/propensity-matched-comparison-of-extrapleural-pneumonectomy-and-pleurectomy-decortication-for-mesothelioma-patients%C3%A2
#8
Arthur Kostron, Martina Friess, Ilhan Inci, Sven Hillinger, Didier Schneiter, Hans Gelpke, Rolf Stahel, Burkhardt Seifert, Walter Weder, Isabelle Opitz
No abstract text is available yet for this article.
February 10, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/28198461/risk-of-other-cancers-in-families-with-melanoma-novel-familial-links
#9
Christoph Frank, Jan Sundquist, Akseli Hemminki, Kari Hemminki
A family history of cutaneous melanoma ('melanoma') is a well-established risk factor for melanoma. However, less is known about the possible familial associations of melanoma with other discordant cancers. A risk for discordant cancer may provide useful information about shared genetic and environmental risk factors and it may be relevant background data in clinical genetic counseling. Using the Swedish Family-Cancer Database, we assessed the relative risk (RR) for any cancer in families with increasing numbers of first-degree relatives diagnosed with melanoma, including multiple melanoma, and in reverse order RR for melanoma in families of multiple discordant cancers...
February 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28197653/does-selective-pleural-irradiation-of-malignant-pleural-mesothelioma-allow-radiation-dose-escalation-a-planning-study
#10
A Botticella, G Defraene, K Nackaerts, C Deroose, J Coolen, P Nafteux, B Vanstraelen, S Joosten, L A W Michiels, S Peeters, D De Ruysscher
BACKGROUND: After lung-sparing radiotherapy for malignant pleural mesothelioma (MPM), local failure at sites of previous gross disease represents the dominant form of failure. Our aim is to investigate if selective irradiation of the gross pleural disease only can allow dose escalation. MATERIALS AND METHODS: In all, 12 consecutive stage I-IV MPM patients (6 left-sided and 6 right-sided) were retrospectively identified and included. A magnetic resonance imaging-based pleural gross tumor volume (GTV) was contoured...
February 14, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28197633/pim1-knockdown-inhibits-cell-proliferation-and-invasion-of-mesothelioma-cells
#11
Amany Sayed Mawas, Vishwa Jeet Amatya, Rui Suzuki, Kei Kushitani, Mouchira M Mohi El-Din, Yukio Takeshima
Malignant mesothelioma is a major asbestos-related cancer with prolonged time lapse from the first exposure of asbestos to the development of mesothelioma. Most of mesothelioma patients show very poor prognosis, thus, an urgent improvement of its treatment is required by development of novel therapeutic strategies. RNA interference (RNAi) is a powerful tool in post-genomic research and cancer therapy through inhibition of gene expression. In the present study, we analyzed the function of PIM1 on mesothelioma cell lines with its knockdown by siRNA transfection...
March 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28197626/kdm6a-and-kdm6b-altered-expression-in-malignant-pleural-mesothelioma
#12
Sian Cregan, Maeve Breslin, Gerard Roche, Sigrid Wennstedt, Lauren MacDonagh, Cinaria Albadri, Yun Gao, Kenneth J O'Byrne, Sinead Cuffe, Stephen P Finn, Steven G Gray
Malignant pleural mesothelioma (MPM) is a rare aggressive cancer of the pleura primarily associated with prior exposure to asbestos. The current standard of care for patients suffering from MPM is a combination of cisplatin and pemetrexed (or alternatively cisplatin and raltitrexed). Most patients, however, die within 24 months of diagnosis. New therapies are therefore urgently required for this disease. Inflammation is thought to be a key element in the pathogenesis of MPM, and recently Kdm6 family members (Kdm6a and Kdm6b) have been identified as playing important roles in inflammatory processes...
March 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28197385/prognostic-and-predictive-aspects-of-the-tumor-immune-microenvironment-and-immune-checkpoints-in-malignant-pleural-mesothelioma
#13
Elly Marcq, Vasiliki Siozopoulou, Jorrit De Waele, Jonas van Audenaerde, Karen Zwaenepoel, Eva Santermans, Niel Hens, Patrick Pauwels, Jan P van Meerbeeck, Evelien L J Smits
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor prognosis and an increasing incidence, for which novel therapeutic strategies are urgently required. Since the immune system has been described to play a presumed role in the protection against MPM, characterization of its tumor immune microenvironment (TME) and immune checkpoints can identify new immunotherapeutic targets and their predictive and/or prognostic value. To characterize the TME and the immune checkpoint expression profile, we performed immunohistochemistry (IHC) on formalin-fixed paraffin embedded (FFPE) tissue sections from 54 MPM patients (40 at time of diagnosis; 14 treated with chemotherapy)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28196068/comparison-of-outcomes-following-a-cytological-or-histological-diagnosis-of-malignant-mesothelioma
#14
Sanjeevan Muruganandan, Helman Alfonso, Peter Franklin, Keith Shilkin, Amanda Segal, Nola Olsen, Alison Reid, Nick de Klerk, Aw Bill Musk, Fraser Brims
BACKGROUND: Survival with the epithelioid subtype of malignant mesothelioma (MM) is longer than the biphasic or sarcomatoid subtypes. There is concern that cytology-diagnosed epithelioid MM may underdiagnose the biphasic subtype. This study examines survival differences between patients with epithelioid MM diagnosed by cytology only and other subtypes diagnosed by histology. METHODS: Demographics, diagnosis method, MM subtype and survival were extracted from the Western Australia (WA) Mesothelioma Registry, which records details of all MM cases occurring in WA...
February 14, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28191281/switching-off-malignant-mesothelioma-exploiting-the-hypoxic-microenvironment
#15
REVIEW
Noushin Nabavi, Kevin L Bennewith, Andrew Churg, Yuzhuo Wang, Colin C Collins, Luciano Mutti
Malignant mesotheliomas are aggressive, asbestos-related cancers with poor patient prognosis, typically arising in the mesothelial surfaces of tissues in pleural and peritoneal cavity. The relative unspecific symptoms of mesotheliomas, misdiagnoses, and lack of precise targeted therapies call for a more critical assessment of this disease. In the present review, we categorize commonly identified genomic aberrations of mesotheliomas into their canonical pathways and discuss targeting these pathways in the context of tumor hypoxia, a hallmark of cancer known to render solid tumors more resistant to radiation and most chemo-therapy...
November 2016: Genes & Cancer
https://www.readbyqxmd.com/read/28189456/long-term-regional-chemotherapy-for-patients-with-epithelial-malignant-peritoneal-mesothelioma-results-in-improved-survival
#16
REVIEW
P H Sugarbaker, D Chang
PURPOSE: Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases or systemic disease. METHODS: Cytoreductive surgery (CRS) is a series of peritonectomy procedures and visceral resections with a goal of complete removal of all visible disease from the abdomen and pelvis. Over 20 years, three protocols investigating increasing efficacy of additional chemotherapy treatments added to CRS have been initiated...
January 29, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28188891/3-2-deoxy-%C3%AE-d-erythro-pentafuranosyl-pyrimido-1-2-%C3%AE-purin-10-3h-one-deoxyguanosine-adducts-of-workers-exposed-to-asbestos-fibers
#17
Stefano Bonassi, Filippo Cellai, Armelle Munnia, Donatella Ugolini, Alfonso Cristaudo, Monica Neri, Mirta Milić, Alessandra Bonotti, Roger W Giese, Marco E M Peluso
Asbestos is the commercial name for a group of silicate minerals naturally occurring in the environment and widely used in the industry. Asbestos exposure has been associated with pulmonary fibrosis, mesothelioma, and malignancies, which may appear after a period of latency of 20-40 years. Mechanisms involved in the carcinogenic effects of asbestos are still not fully elucidated, although the oxidative stress theory suggests that phagocytic cells produce large amounts of reactive oxygen species, due to their inability to digest asbestos fiber...
February 7, 2017: Toxicology Letters
https://www.readbyqxmd.com/read/28188257/validation-of-progression-free-survival-as-a-surrogate-endpoint-for-overall-survival-in-malignant-mesothelioma-analysis-of-cancer-and-leukemia-group-b-and-north-central-cancer-treatment-group-alliance-trials
#18
Xiaofei Wang, Xiaoyi Wang, Lydia Hodgson, Stephen L George, Daniel J Sargent, Nate R Foster, Apar Kishor Ganti, Thomas E Stinchcombe, Jeffrey Crawford, Robert Kratzke, Alex A Adjei, Hedy L Kindler, Everett E Vokes, Herbert Pang
PURPOSE: The aim of this study was to investigate whether progression-free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in malignant mesothelioma. MATERIALS AND METHODS: Individual data were collected from 15 Cancer and Leukemia Group B (615 patients) and 2 North Central Cancer Treatment Group (101 patients) phase II trials. The effects of 5 risk factors for OS and PFS, including age, histology, performance status (PS), white blood cell count, and European Organisation for Research and Treatment of Cancer (EORTC) risk score, were used in the analysis...
February 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28186988/hmgb1-targeting-by-ethyl-pyruvate-suppresses-malignant-phenotype-of-human-mesothelioma
#19
Laura Pellegrini, Jiaming Xue, David Larson, Sandra Pastorino, Sandro Jube, Kelly H Forest, Zeyana Salim Saad-Jube, Andrea Napolitano, Ian Pagano, Vishal S Negi, Marco E Bianchi, Paul Morris, Harvey I Pass, Giovanni Gaudino, Michele Carbone, Haining Yang
Human malignant mesothelioma (MM) is an aggressive cancer linked to asbestos and erionite exposure. We previously reported that High-Mobility Group Box-1 protein (HMGB1), a prototypic damage-associated molecular pattern, drives MM development and sustains MM progression. Moreover, we demonstrated that targeting HMGB1 inhibited MM cell growth and motility in vitro, reduced tumor growth in vivo, and prolonged survival of MM-bearing mice. Ethyl pyruvate (EP), the ethyl ester of pyruvic acid, has been shown to be an effective HMGB1 inhibitor in inflammation-related diseases and several cancers...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28185919/rheostatic-cd44-isoform-expression-and-its-association-with-oxidative-stress-in-human-malignant-mesothelioma
#20
Shan Hwu Chew, Yasumasa Okazaki, Shinya Akatsuka, Shenqi Wang, Li Jiang, Yuuki Ohara, Fumiya Ito, Hideyuki Saya, Yoshitaka Sekido, Shinya Toyokuni
CD44 exists as a standard (CD44s) isoform and different variant isoforms (CD44v) due to alternative splicing. While the complex nature of these different isoforms has not been fully elucidated, CD44v expression has been shown to exert oncogenic effects by promoting tumor progression, metastasis and resistance of tumor cells to chemotherapy. One of the CD44v isoforms, CD44v8-10, was recently shown to protect cancer cells from oxidative stress by increasing the synthesis of glutathione (GSH). However, data regarding CD44 isoform expression in malignant mesothelioma (MM) are still lacking...
February 6, 2017: Free Radical Biology & Medicine
keyword
keyword
267
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"